immatics seals €34m financing for development of renal cancer
16 October 2013
Tuebingen-based immatics biotechnologies has closed a €34
million Series D financing round to fund development of its lead
multi-peptide cancer vaccine, IMA901.
The funding round was supported by existing investors including
dievini Hopp Biotech holding, Wellington Partners, MIG-advised funds
and AT Impf GmbH. Under the terms of the fundraising, immatics will
receive the first €12 million tranche of funding immediately.
The company says the new funds will enable it to conclude the
development of the vaccine, including completing all of the
activities necessary to prepare for regulatory filings in the US and
Europe. IMA901 comprises 10 different tumour-associated peptides
(TUMAPs) that are found to be highly over-expressed in the majority
of patients suffering from renal cell carcinoma (RCC).
It is in a pivotal phase 3 trial and has orphan drug designation
in the US and Europe for the treatment of RCC in HLA-A*02 positive
patients. Interim overall survival results are expected in 2014,
with final data in 2015. The trial showed that patients who produced
an immune response to two or more of the TUMAPs contained in IMA901
had a significantly longer survival, as published in Nature
Medicine in 2012.
1. Walter S, Weinschenk T et al. 2012. Multipeptide immune
response to cancer vaccine IMA901 after single-dose cyclophosphamide
associates with longer patient survival. Nature Medicine, published
online: 29 July 2012.
IMA901 is a rationally designed cancer vaccine comprising 10
different tumour-associated peptides (TUMAPs) that are found to be
highly over-expressed in the majority of patients suffering from
renal cell carcinoma (RCC). IMA901 is a peptide-based vaccine with a
stable, off-the-shelf formulation and robust and easily scalable